Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65

Benzinga Newsdesk www.benzinga.com Neutral 66.7%

Neg 0% Neu 66.7% Pos 0%

Canaccord Genuity analyst Kyle Mikson initiates coverage on CareDx (NASDAQ:CDNA) with a Buy rating and announces Price Target of $65.